Havrix Junior

Havrix Junior is a hepatitis A vaccine that contains inactivated hepatitis A virus adsorbed on aluminium hydroxide, formulated as a sterile solution for intramuscular injection. The product is supplied in a single‑dose vial without a specified strength, and it is authorized for use in the European Union. Havrix Junior is generally prescribed by health‑care professionals to safely induce active immunity against hepatitis A in pediatric patients.

Havrix Junior is indicated for active immunization against hepatitis A in children and for individuals who may be exposed to the virus.

- Primary prevention of hepatitis A infection in children aged 1 year and older. - Immunization of travelers to regions where hepatitis A is endemic. - Protection of children living in households or communities with known hepatitis A cases. - Use in outbreak settings to quickly establish herd immunity among pediatric populations. - Administration to individuals with occupational exposure to hepatitis A, such as food‑service workers.

Like most vaccines, Havrix Junior may cause mild to moderate reactions, while serious adverse events are rare.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever occurring within 24 hours after vaccination. - Headache or mild fatigue lasting one to two days. - Transient loss of appetite or mild gastrointestinal discomfort. - Mild muscle aches lasting up to 48 hours. - Mild joint pain or stiffness at the injection site. - Mild dizziness or feeling of lightheadedness.

Serious: - Severe allergic reaction (anaphylaxis) with difficulty breathing or hives. - Neurological events such as Guillain‑Barré syndrome, though extremely uncommon. - High‑grade fever persisting beyond 48 hours accompanied by rash. - Severe abdominal pain with vomiting, indicating possible hepatitis.

Before administering Havrix Junior, health‑care providers should evaluate the patient’s medical history and current health status to ensure safe vaccination.

- Confirm that the child is at least 1 year old and meets the age requirements for the vaccine. - Defer vaccination in individuals with a known severe allergic reaction to any component of the product. - Postpone the dose if the child has an acute moderate or severe illness with fever. - Assess for immunocompromised conditions, as response to the vaccine may be reduced. - Discuss the benefits and risks with caregivers of children who have a history of seizures. - Ensure that the injection is given intramuscularly in the anterolateral thigh for optimal absorption.

Havrix Junior does not have many documented drug interactions, but certain medications and vaccines may influence its immunogenicity or safety profile.

Avoid: - Concurrent administration with live attenuated vaccines (e.g., measles‑mumps‑rubella) without appropriate spacing. - Use of immunoglobulin products within 14 days before or after vaccination, which may reduce antibody response.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish vaccine effectiveness; monitor antibody levels. - Antipyretics such as acetaminophen can be given to manage post‑vaccination fever, but routine prophylactic use may blunt the immune response. - Severe allergic history warrants careful observation after injection. - Pregnant women should be evaluated individually, as safety data are limited.